Randomized Study of Obicetrapib as an Adjunct to Statin Therapy

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 120 participants.

Also called NCT04753606

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 120 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04753606
Main results
  • Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial Nature medicine, 2022-08 DOI, PubMed 35953719

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04753606. Randomized; quadruple masking; primary purpose treatment. Start 2021-02-18 (actual); primary completion 2021-05-24 (actual). Results posted on 2024-06-11.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Randomized Study of Obicetrapib as an Adjunct to Statin Therapy
Acronym
ROSE
Condition
Dyslipidemias
Condition
High Cholesterol
Condition
Hypercholesterolemia
Intervention (Drug)
Obicetrapib
Lead sponsor
NewAmsterdam Pharma (class: industry)

Record details

Record id
cardio:ct-nct04753606
Content hash
40f38d2d63f84e754633607c7324036f2a9f82319c561df11fc1d4999b7b3517